Page last updated: 2024-09-05

lenalidomide and Leukocytopenia

lenalidomide has been researched along with Leukocytopenia in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Bai, H; Fang, BJ; Fu, WJ; Liao, AJ; Lu, J; Niu, T; Wang, YF; Zhao, HG1
Burgstaller, S; Fridrik, M; Gisslinger, H; Hojas, S; Kühr, T; Ludwig, H; Mayrbäurl, B; Pöhnl, R; Pötscher, M; Schlögl, E; Thaler, J; Zauner, D1
Liljefors, M; Rossmann, E; Ullenhag, GJ1
Bleickardt, E; Chou, T; Iida, S; Kinoshita, G; Miyoshi, M; Nagai, H; Pandya, D; Robbins, M1
Chou, T; Handa, H; Ishizawa, K; Kase, Y; Suzuki, K; Takubo, T1
Ervin-Haynes, A; Habermann, TM; Justice, G; Lossos, IS; McBride, K; Pietronigro, D; Takeshita, K; Tuscano, JM; Vose, JM; Wiernik, PH; Wride, K; Zeldis, JB1
Atanackovic, D; Ayuk, F; Bacher, U; Badbaran, A; Blaise, D; El-Cheikh, J; Fehse, B; Hildebrandt, Y; Hoffmann, F; Kröger, N; Lioznov, M; Mohty, M; Schilling, G; Wolschke, C; Zander, AR1

Trials

5 trial(s) available for lenalidomide and Leukocytopenia

ArticleYear
Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial.
    BMC cancer, 2022, Jul-01, Volume: 22, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Leukopenia; Multiple Myeloma; Prospective Studies; Thalidomide

2022
A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.
    PloS one, 2015, Volume: 10, Issue:4

    Topics: Adenocarcinoma; Administration, Oral; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dalteparin; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Injections, Intravenous; Lenalidomide; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreas; Pancreatic Neoplasms; Thalidomide

2015
Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.
    International journal of hematology, 2017, Volume: 105, Issue:3

    Topics: Aged; Antibodies, Monoclonal, Humanized; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lenalidomide; Leukopenia; Lymphopenia; Male; Middle Aged; Multiple Myeloma; Recurrence; Salvage Therapy; Signaling Lymphocytic Activation Molecule Family; Thalidomide; Treatment Outcome

2017
Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.
    International journal of hematology, 2017, Volume: 105, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Boron Compounds; Dexamethasone; Drug Administration Schedule; Female; Glycine; Humans; Lenalidomide; Leukopenia; Male; Multiple Myeloma; Proteasome Inhibitors; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia

2017
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
    British journal of haematology, 2009, Volume: 145, Issue:3

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukopenia; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutropenia; Recurrence; Thalidomide; Thrombocytopenia; Treatment Outcome

2009

Other Studies

2 other study(ies) available for lenalidomide and Leukocytopenia

ArticleYear
Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis.
    Wiener klinische Wochenschrift, 2013, Volume: 125, Issue:7-8

    Topics: Aged; Aged, 80 and over; Anemia; Austria; Dose-Response Relationship, Drug; Female; Humans; Immunologic Factors; Lenalidomide; Leukopenia; Male; Middle Aged; Primary Myelofibrosis; Thalidomide; Thrombocytopenia; Treatment Outcome

2013
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.
    Bone marrow transplantation, 2010, Volume: 45, Issue:2

    Topics: Hematopoietic Stem Cell Transplantation; HLA-DR Antigens; Humans; Killer Cells, Natural; Lenalidomide; Leukopenia; Multiple Myeloma; Recurrence; Salvage Therapy; T-Lymphocytes; Thalidomide; Thrombocytopenia; Treatment Outcome

2010